Press releases, CEVEC press releases

CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications

CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products
With the introduction of GMP rh TGF-ß1, CellGenix further expands one of the broadest portfolios of GMP cytokines and growth factors for the cell and gene therapy industry
CEVEC’s CAP®Go technology allows access to GMP-grade cytokines such as TGF-ß1 requiring human post-translational modifications which are not possible by using bacterial expression systems
Successful launch further proves the robustness and efficiency of CEVEC’s CAP®Go technology for the production of complex glycoproteins

Cologne, Germany, December 19, 2019

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s cooperation partner CellGenix GmbH, a leading global supplier of GMP raw materials for cell and gene therapy and regenerative medicine, has launched CellGenix® GMP rh TGF-ß1 for cell and gene therapy applications based on CEVEC’s proprietary CAP®Go technology.

CEVEC PRESS RELEASES

CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications

CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

CEVEC Grants Full Distribution Rights for CAP®-CDM Cell Culture Medium and CAP®-CDM Feed to Xell

CEVEC strengthens its Scientific Advisory Board with the appointment of gene therapy specialist J. Fraser Wright, Ph.D.

CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP®Go technology

CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP®Go technology-derived TGF-Beta1 for ex vivo cell culture

CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

CEVEC has been granted a new CAP®Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

CEVEC LICENSES CAP®GO TECHNOLOGY IN THE FIELD OF VETERINARY VACCINES

CEVEC AND PLASMIDFACTORY ANNOUNCE COLLABORATION REGARDING ADENO-ASSOCIATED VIRUS (AAV) PRODUCTION

CEVEC, MEDAC AND PROVECS MEDICAL ENTER INTO FAR-REACHING ADENOVIRAL VECTOR COLLABORATION IN ONCOLOGY

CEVEC LICENSES CAP® TECHNOLOGIES FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VACCINES AGAINST ZIKA VIRUS INFECTIONS

CEVEC SUBMITS BIOLOGICS MASTER FILE (BB-MF) FOR CAP® TECHNOLOGY TO THE U.S. FDA

CEVEC FURTHER STRENGTHENS ORGANIZATION TO DRIVE INDUSTRIALIZATION AND COMMERCIALIZATION OF CAP® TECHNOLOGIES

CEVEC AND PARAGON BIOSERVICES ENTER INTO COMPREHENSIVE COLLABORATION TO ROLL OUT CAP® TECHNOLOGIES IN NORTH AMERICA

CEVEC’S CAP®GT SETS A NEW STANDARD THROUGH RCA-FREE PRODUCTION OF ADENOVIRAL VECTORS FOR GENE THERAPY APPLICATIONS

CEVEC INTENSIFIES ITS MARKETING ACTIVITIES, PRESENTING AT VARIOUS RENOWNED SCIENTIFIC CONFERENCES IN EUROPE AND THE US

CEVEC AND BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE ENTER INTO A COOPERATION AND LICENSE AGREEMENT ON CEVEC’S PROPRIETARY CAP®GT TECHNOLOGY

CEVEC AND BIOLAMINA COMBINE TECHNOLOGY LEADERSHIP FOR COMMERCIAL PRODUCTION OF RECOMBINANT LAMININS FOR EX VIVO CELL THERAPIES

CEVEC STRENGTHENS TEAM TO EXECUTE RAPID GROWTH STRATEGY

CEVEC and CellGenix sign collaboration and license agreement for CEVEC’s proprietary CAP®Go technology

CEVEC AND GÉNÉTHON SIGN A COLLABORATION AGREEMENT TO DEVELOP LENTIVIRAL VECTOR PACKAGING CELL LINES BASED ON CEVEC’S PROPRIETARY CAP®GT TECHNOLOGY

CEVEC INTRODUCES CAP®GT CELL-EXPRESSION SYSTEM FOR SCALABLE VIRAL GENE THERAPY VECTOR PRODUCTION

CEVEC RAISES € 4.5 MILLION IN A FINANCING ROUND TO COMMERCIALIZE ITS LEADING CAP® BASED TECHNOLOGIES

CEVEC’S CAP®GO DERIVED RECOMBINANT PLACENTAL HUMAN ALKALINE PHOSPHATASE SHOWS SUPERIOR RESULTS IN A PRECLINICAL STUDY

CEVEC GRANTS LICENSE TO BIOTEST AG FOR PRODUCTION OF TAILOR-MADE GLYCOPROTEINS

CEVEC INTRODUCES CAP®GO EXPRESSION SYSTEMS FOR SCALABLE PRODUCTION OF TAILOR-MADE GLYCOPROTEINS

CEVEC ANNOUNCES APPOINTMENT OF LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS AS CHIEF EXECUTIVE OFFICER

CEVEC: CAP® DERIVED RECOMBINANT C1 INHIBITOR MATCHES BERINERT® IN ANIMAL STUDY

CEVEC INTRODUCES CMO SERVICES FOR THE CGMP MANUFACTURING OF CAP-BASED CLINICAL MATERIALS

CEVEC INTRODUCES CAP®GT CELL-EXPRESSION SYSTEM FOR SCALABLE
VIRAL GENE THERAPY VECTOR PRODUCTION

CEVEC ANNOUNCES APPOINTMENT OF
LIFE SIENCES INDUSTRY EXPERT FRANK UBAGS
AS CHIEF EXECUTIVE OFFICER

CEVEC INTRODUCES CMO SERVICES
FOR THE CGMP MANUFACTURING OF CAP-BASED
CLINICAL MATERIALS